Analysis of the human pancreatic stellate cell secreted proteome

Pancreas

Volumn 40, Issue 4, 2011, Pages 557-566

  Wehr, Angela Y ^a   Furth, Emma E ^b   Sangar, Vineet ^a   Blair, Ian A ^a   Yu, Kenneth H ^c  

^a Center for Cancer Pharmacology and Excellence in Environmental Toxicology   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Pancreatic cancer; pancreatic stellate cells; pancreatitis; RLT PSC; secretome; tumor microenvironment

Indexed keywords

EZRIN; LIPOCORTIN 2; PROTEOME; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL COMMUNICATION; CELL CULTURE; CELL DIVISION; CELL LINE; CELL MOTILITY; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS CELL; PANCREATITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STELLATE CELL; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; WOUND HEALING;

CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREAS; PANCREATIC NEOPLASMS; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 79955068416     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318214efaf     Document Type: Article

References (60)

1. Apte MV, Haber PS, Applegate TL, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut. 1998; 43(1):128-133. (Pubitemid 28335501)
2. Bachem MG, Schneider E, Gross H, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998; 115(2):421-432.
3. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene. 2002; 21(29):4587-4594. (Pubitemid 34785735)
4. Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007; 117(1):50-59. (Pubitemid 46048449)
5. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004; 29(3):179-187. (Pubitemid 39304974)
6. Aoki H, Ohnishi H, Hama K, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol. 2007; 292(1):C259-C268. (Pubitemid 46115136)
7. Bachem MG, Zhou Z, Zhou S, et al. Role of stellate cells in pancreatic fibrogenesis associated with acute and chronic pancreatitis. J Gastroenterol Hepatol. 2006; 21(suppl 3):S92-S96. (Pubitemid 44266560)
8. 1 as a novel CCN2 receptor. Gastroenterology. 2005; 129(3):1019-1030. (Pubitemid 41242692)
9. Phillips PA, Wu MJ, Kumar RK, et al. Cell migration: a novel aspect of pancreatic stellate cell biology. Gut. 2003; 52(5):677-682. (Pubitemid 36528869)
10. Shek FW, Benyon RC, Walker FM, et al. Expression of transforming growth factor-A1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am J Pathol. 2002; 160(5):1787-1798. (Pubitemid 34525658)
11. Yu KH, Barry CG, Austin D, et al. Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res. 2009; 8(3):1565-1576.
12. Jesnowski R, Furst D, Ringel J, et al. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by Matrigel and N-acetylcysteine. Lab Invest. 2005; 85(10):1276-1291. (Pubitemid 41348642)
13. Yocum AK, Yu K, Oe T, et al. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res. 2005; 4(5):1722-1731. (Pubitemid 41464800)
14. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000; 28(1):27-30. (Pubitemid 30047706)
15. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):3.
16. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57.
17. Michalski CW, Gorbachevski A, Erkan M, et al. Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. J Transl Med. 2007; 5:63.
18. Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005; 128(4):907-921. (Pubitemid 40523543)
19. Schneiderhan W, Diaz F, Fundel M, et al. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J Cell Sci. 2007; 120(Pt 3):512-519. (Pubitemid 46332514)
20. Bachem MG, Zhou S, Buck K, et al. Pancreatic stellate cells - role in pancreas cancer. Langenbecks Arch Surg. 2008; 393(6):891-900.
21. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008; 68(3):918-926. (Pubitemid 351206771)
22. Philips PA, McCarroll JA, Park S, et al. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut. 2003; 52(2):275-282. (Pubitemid 36115072)
23. Smith R, Xue A, Gill A, et al. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg. 2007; 31(3): 493-502. (Pubitemid 46356075)
24. Friess H, Cantero D, Graber H, et al. Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology. 1997; 113(3):904-913. (Pubitemid 27381151)
25. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost. 2001; 86(6):1416-1420. (Pubitemid 34007513)
26. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997; 75(3):388-395. (Pubitemid 27051054)
27. Takeuchi Y, Nakao A, Harada A, et al. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol. 1993; 88(11): 1928-1933. (Pubitemid 23324412)
28. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67(19):9518-9527. (Pubitemid 47535942)
29. Wang PH, Ko JL, Chang H, et al. Clinical significance of high nm23-H1 expression in intraepithelial neoplasia and early-stage squamous cell carcinoma of the uterine cervix. Gynecol Obstet Invest. 2003; 55(1): 14-19. (Pubitemid 36302384)
30. Ferenc T, Lewinski A, Lange D, et al. Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors. Pol J Pathol. 2004; 55(4):149-153. (Pubitemid 40321623)
31. Leary JA, Kerr J, Chenevix-Trench G, et al. Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer. Int J Cancer. 1995; 64(3):189-195.
32. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007; 51(2-4):105-111. (Pubitemid 47179898)
33. Yu J, Tao Q, Cheung KF, et al. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology. 2008; 48(2):508-518.
34. Hibi K, Westra WH, Borges M, et al. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol. 1999; 155(3): 711-715. (Pubitemid 29426816)
35. Yamazaki T, Hibi K, Takase T, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002; 8(1):192-195. (Pubitemid 34101477)
36. Tezel E, Hibi K, Nagasaka T, et al. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res. 2000; 6(12):4764-4767. (Pubitemid 32110417)
37. Curtis CD, Likhite VS, McLeod IX, et al. Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor > alters estrogen-responsive gene expression. Cancer Res. 2007; 67(21):10600-10607. (Pubitemid 350070837)
38. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 2007; 13(35):3568-3575. (Pubitemid 350238927)
39. Duncan R, Carpenter B, Main LC, et al. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2008; 98(2):426-433. (Pubitemid 351161239)
40. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994; 269(33):21191-21197.
41. Ozaki K, Nagata M, Suzuki M, et al. Isolation and characterization of a novel human pancreas-specific gene, pancpin, that is down-regulated in pancreatic cancer cells. Genes Chromosomes Cancer. 1998; 22(3):179-185. (Pubitemid 28262194)
42. Xiao G, Liu YE, Gentz R, et al. Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells. Proc Natl Acad Sci U S A. 1999; 96(7):3700-3705. (Pubitemid 29168973)
43. Park YP, Choi SC, Kim JH, et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer. 2007; 120(4): 813-820. (Pubitemid 46175401)
44. Berberat PO, Friess H, Wang L, et al. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem. 2001; 49(4):539-549. (Pubitemid 32295176)
45. Hughes RC. Galectins as modulators of cell adhesion. Biochimie. 2001; 83(7):667-676. (Pubitemid 32821230)
46. Florenes VA, Aamdal S, Myklebost O, et al. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992; 52(21):6088-6091.
47. Youn B, Kim HD, Kim J. Nm23-H1/nucleoside diphosphate kinase as a key molecule in breast tumor angiogenesis. Expert Opin Ther Targets. 2008; 12(11):1419-1430.
48. MacDonald NJ, de la RA, Benedict MA, et al. A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential. J Biol Chem. 1993; 268(34):25780-25789. (Pubitemid 23358195)
49. Murakami M, Meneses PI, Lan K, et al. The suppressor of metastasis Nm23-H1 interacts with the Cdc42 Rho family member and the pleckstrin homology domain of oncoprotein Dbl-1 to suppress cell migration. Cancer Biol Ther. 2008; 7(5):677-688.
50. Waikel RL, Kawachi Y, Waikel PA, et al. Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet. 2001; 28(2):165-168. (Pubitemid 32538063)
51. Skonier J, Bennett K, Rothwell V, et al. beta ig-h3: a transforming growth factor-β-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol. 1994; 13(6):571-584.
52. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996; 12:697-715. (Pubitemid 26422728)
53. Hourihan RN, O'Sullivan GC, Morgan JG. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res. 2003; 23(1A):161-165. (Pubitemid 36358513)
54. Ivanov SV, Ivanova AV, Salnikow K, et al. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun. 2008; 370(4):536-540.
55. Kim HJ, Kim YM, Lim S, et al. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 2009; 28(1):117-127.
56. Valdman A, Fang X, Pang ST, et al. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol. 2005; 48(5):852-857.
57. Akisawa N, Nishimori I, Iwamura T, et al. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun. 1999; 258(2): 395-400. (Pubitemid 29287062)
58. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002; 3(8):586-599.
59. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10(2):182-186. (Pubitemid 38524889)
60. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004; 10(2):175-181. (Pubitemid 38524888)